FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130184874> ?p ?o ?g. }

• W2130184874 endingPage "38" @default.
• W2130184874 startingPage "31" @default.
• W2130184874 abstract "After completing this course, the reader will be able to: Discuss new vehicles for the initial release of practice-relevant phase III clinical trial data. Describe the limited educational impact of such information transfer vehicles on the medical oncology community. Explain the potential risks to medical oncologists and their patients because of underinformed or non–evidence-based therapeutic recommendations involving new indications for commercially available agents. Discuss the development of new strategies for effective knowledge transfer of preliminary, practice-relevant, clinical trial data. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com Background. Practicing oncologists are expected to easily assimilate large amounts of rapidly evolving clinical data. We hypothesized that U.S. oncologists rapidly familiarize themselves with new, practice-relevant, phase III clinical trial data. We tested this hypothesis in relation to the release of phase III data from the Eastern Cooperative Oncology Group 4599 trial on the role of bevacizumab in advanced non-small cell lung cancer (NSCLC). Methods. We queried approximately 310 medical oncologists concerning their awareness of the bevacizumab data within 1 and 3 weeks after the data release or immediately after the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO). Results. Prior to the ASCO meeting, 57% and 56% of the oncologists in the two research meetings, respectively, indicated “awareness” of the data release. Less than 25% selected an accurate descriptor of the released information from a short list of plausible options. After the ASCO meeting, the figures were 88% and 34%. Over 50% said they plan to use bevacizumab in NSCLC treatment as soon as reimbursement is secure. Eighty-two percent said they plan to use it in second- or third-line treatment; 56% said they plan to use it during second-line chemotherapy despite progression during first-line use. A large majority intend to use bevacizumab in dosages, tumor types, drug combinations, and/or patients not specifically supported by phase III data. Conclusion. Release of clinically relevant phase III data through electronic and print media is a poor vehicle for informing U.S. medical oncologists. For a commercially available agent, this can have important implications for potential use in untested and potentially unsafe clinical settings. Effective educational strategies for dealing with the new paradigm of “instant” release of clinical data need to be developed." @default.
• W2130184874 created "2016-06-24" @default.
• W2130184874 creator A5011945299 @default.
• W2130184874 creator A5024049602 @default.
• W2130184874 creator A5035911953 @default.
• W2130184874 creator A5040617350 @default.
• W2130184874 creator A5063533830 @default.
• W2130184874 creator A5069843364 @default.
• W2130184874 creator A5071912108 @default.
• W2130184874 creator A5075108469 @default.
• W2130184874 creator A5088962737 @default.
• W2130184874 date "2006-01-01" @default.
• W2130184874 modified "2023-09-27" @default.
• W2130184874 title "How Do U.S. Medical Oncologists Learn and Apply New Clinical Trials Information from Press Releases in Nonmedical Media? A Case Study Based on ECOG 4599" @default.
• W2130184874 cites W2100785570 @default.
• W2130184874 cites W2157769714 @default.
• W2130184874 doi "https://doi.org/10.1634/theoncologist.11-1-31" @default.
• W2130184874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16401711" @default.
• W2130184874 hasPublicationYear "2006" @default.
• W2130184874 type Work @default.
• W2130184874 sameAs 2130184874 @default.
• W2130184874 citedByCount "3" @default.
• W2130184874 crossrefType "journal-article" @default.
• W2130184874 hasAuthorship W2130184874A5011945299 @default.
• W2130184874 hasAuthorship W2130184874A5024049602 @default.
• W2130184874 hasAuthorship W2130184874A5035911953 @default.
• W2130184874 hasAuthorship W2130184874A5040617350 @default.
• W2130184874 hasAuthorship W2130184874A5063533830 @default.
• W2130184874 hasAuthorship W2130184874A5069843364 @default.
• W2130184874 hasAuthorship W2130184874A5071912108 @default.
• W2130184874 hasAuthorship W2130184874A5075108469 @default.
• W2130184874 hasAuthorship W2130184874A5088962737 @default.
• W2130184874 hasBestOaLocation W21301848741 @default.
• W2130184874 hasConcept C121608353 @default.
• W2130184874 hasConcept C126322002 @default.
• W2130184874 hasConcept C143998085 @default.
• W2130184874 hasConcept C151730666 @default.
• W2130184874 hasConcept C17744445 @default.
• W2130184874 hasConcept C19527891 @default.
• W2130184874 hasConcept C199539241 @default.
• W2130184874 hasConcept C2776598537 @default.
• W2130184874 hasConcept C2776694085 @default.
• W2130184874 hasConcept C2777267654 @default.
• W2130184874 hasConcept C2777802072 @default.
• W2130184874 hasConcept C2779473830 @default.
• W2130184874 hasConcept C2779974597 @default.
• W2130184874 hasConcept C512399662 @default.
• W2130184874 hasConcept C535046627 @default.
• W2130184874 hasConcept C71924100 @default.
• W2130184874 hasConcept C86803240 @default.
• W2130184874 hasConceptScore W2130184874C121608353 @default.
• W2130184874 hasConceptScore W2130184874C126322002 @default.
• W2130184874 hasConceptScore W2130184874C143998085 @default.
• W2130184874 hasConceptScore W2130184874C151730666 @default.
• W2130184874 hasConceptScore W2130184874C17744445 @default.
• W2130184874 hasConceptScore W2130184874C19527891 @default.
• W2130184874 hasConceptScore W2130184874C199539241 @default.
• W2130184874 hasConceptScore W2130184874C2776598537 @default.
• W2130184874 hasConceptScore W2130184874C2776694085 @default.
• W2130184874 hasConceptScore W2130184874C2777267654 @default.
• W2130184874 hasConceptScore W2130184874C2777802072 @default.
• W2130184874 hasConceptScore W2130184874C2779473830 @default.
• W2130184874 hasConceptScore W2130184874C2779974597 @default.
• W2130184874 hasConceptScore W2130184874C512399662 @default.
• W2130184874 hasConceptScore W2130184874C535046627 @default.
• W2130184874 hasConceptScore W2130184874C71924100 @default.
• W2130184874 hasConceptScore W2130184874C86803240 @default.
• W2130184874 hasIssue "1" @default.
• W2130184874 hasLocation W21301848741 @default.
• W2130184874 hasLocation W21301848742 @default.
• W2130184874 hasOpenAccess W2130184874 @default.
• W2130184874 hasPrimaryLocation W21301848741 @default.
• W2130184874 hasRelatedWork W2038723842 @default.
• W2130184874 hasRelatedWork W2063123552 @default.
• W2130184874 hasRelatedWork W2084590786 @default.
• W2130184874 hasRelatedWork W2092151800 @default.
• W2130184874 hasRelatedWork W2110506075 @default.
• W2130184874 hasRelatedWork W2130184874 @default.
• W2130184874 hasRelatedWork W2167750533 @default.
• W2130184874 hasRelatedWork W2168718355 @default.
• W2130184874 hasRelatedWork W2568863723 @default.
• W2130184874 hasRelatedWork W4295758394 @default.
• W2130184874 hasVolume "11" @default.
• W2130184874 isParatext "false" @default.
• W2130184874 isRetracted "false" @default.
• W2130184874 magId "2130184874" @default.
• W2130184874 workType "article" @default.